Breaking News Instant updates and real-time market news.

MSFT

Microsoft

$60.26

-0.83 (-1.36%)

, LNKD

Acquired by MSFT

$195.21

-0.03 (-0.02%)

13:31
12/01/16
12/01
13:31
12/01/16
13:31

EU likely to clear Microsoft-LinkedIn deal with conditions, Dow Jones says

The EU conditions are based "largely" on remedies that Microsoft offered in November, Dow Jones added, citing sources.

MSFT

Microsoft

$60.26

-0.83 (-1.36%)

LNKD

Acquired by MSFT

$195.21

-0.03 (-0.02%)

CRM

Salesforce

$68.78

-3.22 (-4.47%)

  • 01

    Dec

MSFT Microsoft
$60.26

-0.83 (-1.36%)

12/01/16
OPCO
12/01/16
NO CHANGE
OPCO
Outperform
Amazon continues to attack large, emerging opportunities, says Oppenheimer
Commenting on the first day of Amazon's (AMZN) Amazon Web Services re:Invent conference, Oppenheimer analyst Jason Helfstein notes that AWS targeted Oracle's (ORCL) database services and highlighted more artificial intelligence functionality in line with Google's (GOOG; GOOGL)/Microsoft (MSFT). The analyst says Amazon also touched on its partnership with VMware (VMW), which should help enterprise migration. Helfstein believes AWS continues to attack large/emerging opportunities while continuing to simplify/automate the development process. He reiterates an Outperform rating on Amazon's shares.
11/18/16
OPCO
11/18/16
NO CHANGE
OPCO
Public cloud infrastructure market will be $62B by 2020, says Oppenheimer
Oppenheimer analyst Timothy Horan says "the race is on" for public cloud providers to get as much of their customers' data on their respective cloud platforms as possible. The analyst believes Amazon (AMZN) Web Services, Microsoft (MSFT), and Alphabet's Google (GOOG; GOOGL) have ambitions to become the dominant OS of the cloud, and to do so these companies will aim to have integrated solutions from the infrastructure layer to services through first-party offerings and/or the development of a strong partner channel. He views AWS as the primary wholesale cloud platform and Microsoft as the enterprise platform. However, given the relative immaturity of the market and the massive $1T opportunity, all three have been successful focusing on multiple segments, Horan adds, noting that he expects the public cloud infrastructure market to be $62B by 2020.
11/17/16
11/17/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Buy from Neutral at Goldman with analyst Heather Bellini saying Azure is the number two market share vendor in the cloud space, and has grown 100% or more year-over-year eight of the last 10 quarters. 2. Time Warner (TWX) upgraded to Buy from Sell at MoffettNathanson. 3. First Solar (FSLR) upgraded at JMP Securities with analyst Joseph Osha citing valuation. 4. KBR (KBR) upgraded to Buy from Neutral at BofA Merrill Lynch with analyst Anna Kaminskaya saying she expects structurally higher defense spending to drive a re-rating in KBR and sees less risk of cost overruns in the E&C business given lower reliance on fixed priced contracts and diversification into smaller sized service projects. 5. Liberty Interactive (QVCA) upgraded to Buy from Neutral at BofA Merrill Lynch with analyst Heather Balsky saying she has increased confidence in a return to positive US sales growth and expects multiple expansion as sales improve. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/17/16
GSCO
11/17/16
UPGRADE
Target $68
GSCO
Buy
Microsoft upgraded to Buy from Neutral at Goldman
Goldman Sachs analyst Heather Bellini upgraded Microsoft to Buy from Neutral and raised her price target for the shares to $68 from $60. The software giant closed yesterday up 78c to $59.65. Azure is the number two market share vendor in the cloud space, and has grown 100% or more year-over-year eight of the last 10 quarters, Bellini tells investors in a research note on the public cloud space. She believes Azure can continue to grow revenue and improve margins over time given Microsoft's large customer base and "strong" C-level relationships. The analyst sees upside potential to out-year earnings forecasts for the company.
LNKD Acquired by MSFT
$195.21

-0.03 (-0.02%)

06/15/16
UBSW
06/15/16
DOWNGRADE
Target $196
UBSW
Neutral
LinkedIn downgraded to Neutral from Buy at UBS
UBS analyst Eric Sheridan downgraded LinkedIn (LNKD) to Neutral saying it is unlikely that another bidder to Microsoft (MSFT) will emerge. The analyst, however, "cannot completely rule out this possibility." He raised his price target for LinkedIn shares to $196 from $175.
09/23/16
BOFA
09/23/16
NO CHANGE
Target $55
BOFA
Buy
BofA thinks Verizon deal stays on track despite Yahoo data breach
Bank of America Merrill Lynch analyst Justin Post said that Yahoo's (YHOO) disclosure of the massive data breach impacting over 500M of its users is clearly a negative for the company that could result in email account closures, but he does not anticipate a major impact on Yahoo's business related to this breach, citing as evidence the fact that he is not aware of any significant business impairment or financial liability related to security breaches at LinkedIn (LNKD) in 2012 and at eBay (EBAY) in 2014. Post adds that the Target (TGT) data breach, which did include credit card info, is not directly comparable to Yahoo's breach. For Verizon (VZ) to back out of its acquisition agreement, Post thinks the company would need to assume Yahoo acted in bad faith during negotiations and that the Yahoo asset is impaired or comes with significant liability, neither of which he sees as being the case. The analyst keeps a Buy rating on Yahoo and bumped his target on the shares to $55 from $53, citing an increased price target on Alibaba (BABA) that a peer at the firm recently set.
06/15/16
NOMU
06/15/16
DOWNGRADE
NOMU
Neutral
LinkedIn downgraded to Neutral from Buy at Nomura
LinkedIn (LNKD) is being acquired by Microsoft (MSFT) for $196 per share in cash.
06/15/16
RBCM
06/15/16
DOWNGRADE
RBCM
Sector Perform
LinkedIn downgraded to Sector Perform from Outperform at RBC Capital
LinkedIn (LNKD) is being acquired by Microsoft (MSFT) for $196 per share in cash.
CRM Salesforce
$68.78

-3.22 (-4.47%)

11/18/16
BMUR
11/18/16
NO CHANGE
Target $110
BMUR
Buy
Salesforce acquisition strategy a key growth driver, says Brean Capital
Brean Capital analyst Yun Kim noted Salesforce reported strong Q3 results and strong implied billings guidance. He also acknowledged cautious investor sentiment due to the company's recent pursuit of a large acquisition and believes that could limit valuation multiples. Kim believes a disciplined acquisition strategy serves as a key growth driver for the company, however, and reiterated his Buy rating and $110 price target on Salesforce shares.
11/18/16
11/18/16
NO CHANGE

Salesforce shares should be bought after results, says Pacific Crest
After Salesforce reported stronger than expected results, Pacific Crest analyst Brent Bracelin says that the results were "impressive and surprising." The analyst thinks that the stock could reach $95, and he recommends buying the shares .
11/29/16
COWN
11/29/16
NO CHANGE
Target $95
COWN
Outperform
Salesforce positioned to double revenues organically, says Cowen
Cowen analyst J.Derrick Wood noted Salesforce shares faded following its last beat and raise quarter. He believes the cause was comments by CEO Mark Benioff, who wishes to double the company's revenue in 3-4 years, which many interpreted as bringing a higher risk of M&A dilution/disruption risk. Wood believes the company can double organically, driven by exposure to attractive secular trends around digital transformation, a broadening solution portfolio, and a positioning for the next wave of enterprise applications. Wood reiterated his Outperform rating and $95 price target on Salesforce shares.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $95
ADAM
Buy
Salesforce weakness would be a buying opportunity, says Canaccord
Canaccord analyst Richard Davis noted Salesforce reported good Q3 results and provided in-line guidance. The analyst maintains his positive view on the company's fundamentals and said he would use any pullbacks to build out a full position. Davis reiterated his Buy rating and $95 price target on Salesforce shares.

TODAY'S FREE FLY STORIES

JKHY

Jack Henry

$125.32

0.17 (0.14%)

17:12
01/22/18
01/22
17:12
01/22/18
17:12
Initiation
Jack Henry initiated  »

Jack Henry initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIZ

Assurant

$94.03

-0.05 (-0.05%)

17:10
01/22/18
01/22
17:10
01/22/18
17:10
Syndicate
Breaking Syndicate news story on Assurant »

Assurant files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

FSLR

First Solar

$68.96

-1.07 (-1.53%)

17:08
01/22/18
01/22
17:08
01/22/18
17:08
Technical Analysis
Technical Take: First Solar spikes after tariff decision »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRO

Brown & Brown

$52.25

-0.25 (-0.48%)

17:05
01/22/18
01/22
17:05
01/22/18
17:05
Earnings
Brown & Brown reports Q4 EPS 47c, consensus 42c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EAT

Brinker

$38.39

0.08 (0.21%)

, GS

Goldman Sachs

$261.52

5.4 (2.11%)

17:03
01/22/18
01/22
17:03
01/22/18
17:03
Hot Stocks
Brinker adds James Katzman To Board of Directors »

Brinker (EAT) announces…

EAT

Brinker

$38.39

0.08 (0.21%)

GS

Goldman Sachs

$261.52

5.4 (2.11%)

HSY

Hershey

$109.96

0.59 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 31

    Jan

  • 01

    Feb

CCXI

ChemoCentryx

$8.31

-0.04 (-0.48%)

17:01
01/22/18
01/22
17:01
01/22/18
17:01
Hot Stocks
ChemoCentryx reports 'positive' survival results from CCX872 trial »

ChemoCentryx announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TROW

T. Rowe Price

$117.40

0.05 (0.04%)

16:57
01/22/18
01/22
16:57
01/22/18
16:57
Hot Stocks
T. Rowe Price sees FY18 effective tax rate 24%-27% »

On December 22, 2017, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$75.83

0.23 (0.30%)

16:45
01/22/18
01/22
16:45
01/22/18
16:45
Hot Stocks
Natixis, NYSE enter licensing agreement »

Natixis Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBIO

Catalyst Biosciences

$21.21

1.72 (8.83%)

16:43
01/22/18
01/22
16:43
01/22/18
16:43
Syndicate
Breaking Syndicate news story on Catalyst Biosciences »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRET

Investors Real Estate

$5.74

0.03 (0.53%)

16:40
01/22/18
01/22
16:40
01/22/18
16:40
Hot Stocks
Investors Real Estate completes sale of two additional medical office buildings »

IRET completed the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIC

Flushing Financial

$28.93

-0.1 (-0.34%)

16:39
01/22/18
01/22
16:39
01/22/18
16:39
Hot Stocks
Flushing Financial announces dividend plans for 2018 »

Flushing Financia, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

JMBA

Jamba

$9.14

-0.01 (-0.11%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Syndicate
Jamba 2.1M share Block Trade; price range $8.25-$8.40 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.65

0.1 (0.54%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Earnings
Fulton Financial reports Q4 EPS 19c, consensus 28c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AMGN

Amgen

$192.33

3.05 (1.61%)

16:36
01/22/18
01/22
16:36
01/22/18
16:36
Hot Stocks
Amgen: Aimovig met all primary, secondary endpoints in Phase 3b LIBERTY study »

Amgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN

Amgen

$192.33

3.05 (1.61%)

16:34
01/22/18
01/22
16:34
01/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Amgen »

Amgen: Aimovig met all…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

FL

Foot Locker

$50.37

0.16 (0.32%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
Foot Locker makes strategic investment in Carbon38 »

Foot Locker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPE

EP Energy

$2.48

0.17 (7.36%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
EP Energy sees FY18 $600M-$650M of oil and gas expenditures, »

Sees FY18 81…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$98.06

-0.98 (-0.99%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Darden names Dave George as COO »

Darden Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

, WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Rite Aid provides update on sale of assets to Walgreens Boots Alliance »

Rite Aid Corporation…

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$54.16

0.43 (0.80%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Earnings
Zions Bancorp reports Q4 adjusted EPS 80c, consensus 73c »

Harris H. Simmons,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
EP Energy reports preliminary FY17 production results of 82,300MBoe/d »

Preliminary FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

RMD

ResMed

$87.51

-1.17 (-1.32%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
Breaking Hot Stocks news story on ResMed »

ResMed up 8.5% to $95.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.